Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi8-vi10; doi:10.1093/annonc/mdm216
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maiello, E
Right arrow Articles by Colucci, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maiello, E
Right arrow Articles by Colucci, G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

monoclonal antibodies anti-EGFR and anti-VEGF

Cetuximab: clinical results in colorectal cancer

E Maiello1,*, F Giuliani2, V Gebbia3,4, A Piano1, R Agueli3 and G Colucci2

1 Medical Oncology Unit, Istituto di ricovero e cura a carattere scientifico (IRCCS) Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia
2 Medical Oncology Unit, National Cancer Institute, Bari
3 Medical Oncology Unit, La Maddalena Hospital, Palermo
4 Department of Experimental Oncology and Clinical Applications, University of Palermo, Palermo, Italy

* Correspondence to: Evaristo Maiello, IRCCS Casa Sollievo della Sofferenza, Oncology Unit, Viale Cappuccini 1, 71013 San Giovanni Rotondo, Foggia, Italy. Tel: +39-0882-410-640; Fax: +39-0882-412-792; E-mail: e.maiello{at}operapadrepio.it

In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.

Key words: Cetuximab, colorectal cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.